ライフサイエンスコーパス: invasive fungal infection

1 n blood test may assist is the definition of invasive fungal infection.

2 gitel assay may be most useful for excluding invasive fungal infection.

3 other clinical or laboratory indications of invasive fungal infection.

4 Forty-five patients (11%) developed invasive fungal infection.

5 cally ill patients, often without documented invasive fungal infection.

6 ptimised imaging for patients with suspected invasive fungal infection.

7 severe colitis and are highly susceptible to invasive fungal infection.

8 ystemic antifungal therapy had no documented invasive fungal infection.

9 , including 100 without and 54 with a proven invasive fungal infection.

10 ing the clinical management of patients with invasive fungal infections.

11 singly been reported as the causes of severe invasive fungal infections.

12 f surgical intensive care unit patients with invasive fungal infections.

13 ld be used in unison to aid the detection of invasive fungal infections.

14 lture-based methods may aid the diagnosis of invasive fungal infections.

15 glucan (BG) and is intended for diagnosis of invasive fungal infections.

16 B for the prevention and early treatment of invasive fungal infections.

17 w approaches to prevent, diagnose, and treat invasive fungal infections.

18 cin B or liposomal amphotericin B to prevent invasive fungal infections.

19 reatment and prevention of clinically occult invasive fungal infections.

20 s therapy, particularly for the treatment of invasive fungal infections.

21 of agents available to treat drug-resistant invasive fungal infections.

22 suppressive drugs have a higher incidence of invasive fungal infections.

23 t advances in the diagnosis and treatment of invasive fungal infections.

24 inical courses were not consistent with true invasive fungal infections.

25 thelium could serve as a portal of entry for invasive fungal infections.

26 ies, but data are lacking from patients with invasive fungal infections.

27 medication used for prophylaxis or to treat invasive fungal infections.

28 l yeast Candida albicans is a major cause of invasive fungal infections.

29 that this test has value in the diagnosis of invasive fungal infections.

30 ing an increasing variety of superficial and invasive fungal infections.

31 ul for at least the presumptive diagnosis of invasive fungal infections.

32 ying immunity to mucocutaneous as opposed to invasive fungal infections.

33 ork for developing FTase inhibitors to treat invasive fungal infections.

34 of epidemiology, prevention and treatment of invasive fungal infections.

35 ce of immunogenetics in conferring risks for invasive fungal infections.

36 ] for 5 vs none), sepsis (2.94 [2.70-3.21]), invasive fungal infection (1.20 [1.02-1.42]), and pneumo

37 ] for 5 vs none), sepsis (4.61 [4.34-4.89]), invasive fungal infection (1.24 [1.11-1.39]), and pneumo

38 ral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79

39 fungal infections (1.31; 95% CI, .46-3.72), invasive fungal infections (2.85; .68-11.91), P. jirovec

40 In this cohort, the incidence of invasive fungal infections (36% vs. 7%, P=0.0007) and in

41 Invasive fungal infections, accompanied by high rates of

42 s using factors known to affect the risk for invasive fungal infection after hematopoietic stem-cell

43 tomegalovirus infection is a risk factor for invasive fungal infection after transplantation, we have

44 han fluconazole for long-term prophylaxis of invasive fungal infections after allogeneic hematopoieti

45 an independently significant risk factor for invasive fungal infections after liver transplantation.

46 The mortality attributable to invasive fungal infections among patients with mold infe

47 sidered clinically relevant (2 isolates from invasive fungal infection and 13 isolates from cutaneous

48 recently been approved for the prevention of invasive fungal infection and the treatment of esophagea

49 Six patients (5%) developed invasive fungal infections and 5 patients (4%) had life-

50 ibute to the ability of these fungi to cause invasive fungal infections and allergic diseases.

51 at engraftment is associated with more early invasive fungal infections and more late CMV disease res

52 as an independently significant predictor of invasive fungal infections and was associated with late

53 ungal colonization, prevents superficial and invasive fungal infections, and has no appreciable hepat

54 ls are postulated to provide defense against invasive fungal infection, animal models and human studi

55 Invasive fungal infections are a leading cause of morbid

56 Invasive fungal infections are a major threat for patien

57 Invasive fungal infections are a significant cause of mo

58 Invasive fungal infections are a significant cause of mo

59 Invasive fungal infections are an important cause of mor

60 Invasive fungal infections are an important infection co

61 , ongoing studies of epidemiologic shifts in invasive fungal infections are important.

62 Invasive fungal infections are increasingly common in th

63 Epidemiologic shifts in invasive fungal infections are likely co-travelers with

64 Shifts in invasive fungal infections are occurring as a consequenc

65 Invasive fungal infections are typically difficult to pr

66 of combining C12 or C14 with azoles to treat invasive fungal infections at lower administration doses

67 care unit septic patients without documented invasive fungal infection based on their severity of ill

68 Invasive fungal infections cause considerable morbidity

69 this protection breaks down, superficial and invasive fungal infections cause diseases that range fro

70 Invasive fungal infections cause significant morbidity a

71 Invasive fungal infections cause significant morbidity a

72 We describe a case of invasive fungal infection caused by Volvariella volvacea

73 Invasive fungal infections caused by Neosartorya pseudof

74 selective defect in the host defense against invasive fungal infection, caused by an impaired phagocy

75 is setting is associated with lower rates of invasive fungal infections compared with placebo or no i

76 A biopsy provided an initial diagnosis of an invasive fungal infection consistent with aspergillosis

77 opulation of patients at risk for developing invasive fungal infections continues to increase.

78 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/MSG)

79 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and Mycoses

80 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and Nationa

81 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and Nationa

82 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Nat

83 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Nat

84 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National I

85 ization for Research and Treatment of Cancer Invasive Fungal Infections Cooperative Group/Mycoses Stu

86 Invasive fungal infections developed in 11.1% (2 of 18)

87 Eighteen patients (40%) with invasive fungal infection died, and 13 (72%) of these de

88 aration of amphotericin B as prophylaxis for invasive fungal infections, directed toward liver transp

89 Fungal colonization, proven superficial or invasive fungal infection, drug-related side effects, an

90 Invasive fungal infections due to Aspergillus species ha

91 vival, causes of death, and the incidence of invasive fungal infections early (less than 110 days) an

92 ess morbidity in the cyclophosphamide group (invasive fungal infections, four cyclophosphamide vs no

93 Patients in the invasive fungal infection groups had comparable risk fac

94 Invasive fungal infection has a major impact on the morb

95 Invasive fungal infections have a high rate of morbidity

96 ssic culture techniques for the diagnosis of invasive fungal infections have lead to the emergence of

97 ant recipients have the highest incidence of invasive fungal infection; however, no antifungal prophy

98 In multivariate analysis, the risks of invasive fungal infections (HR, 0.59; 95% CI, 0.3-1.0) a

99 prophylaxis is shown to decrease the risk of invasive fungal infection (IFI) after hematopoietic stem

100 Invasive fungal infection (IFI) following liver transpla

101 ntation but also have increased the risk for invasive fungal infection (IFI) in this population.

102 Invasive fungal infection (IFI) is a serious threat afte

103 Invasive fungal infection (IFI) is associated with high

104 recipients with predefined risk factors for invasive fungal infection (IFI), a prospective phase II

105 termine whether empirical micafungin reduces invasive fungal infection (IFI)-free survival at day 28.

106 Invasive fungal infections (IFI) are a major cause of mo

107 Invasive fungal infections (IFI) remain a serious threat

108 Prompt diagnosis of invasive fungal infections (IFI) remains a challenge.

109 Proven or probable invasive fungal infections (IFI) were evaluated by inten

110 Invasive fungal infections (IFI), particularly those cau

111 in serum has been evaluated in patients with invasive fungal infections (IFIs) and healthy controls a

112 Invasive fungal infections (IFIs) are a major cause of H

113 Invasive fungal infections (IFIs) are life-threatening c

114 Combat trauma wounds with invasive fungal infections (IFIs) are often polymicrobia

115 gh-profile outbreaks have drawn attention to invasive fungal infections (IFIs) as an increasingly imp

116 Invasive fungal infections (IFIs) cause significant morb

117 The incidence of invasive fungal infections (IFIs) in solid organ transpl

118 r developments in diagnosis and treatment of invasive fungal infections (IFIs) that complicate cancer

119 s in liver transplant recipients at risk for invasive fungal infections (IFIs), GM and BG were assess

120 an additional increased risk of non-Candida invasive fungal infections (IFIs).

121 pirical micafungin decreased the rate of new invasive fungal infection in 4 of 128 patients (3%) in t

122 ly, we describe the first case of A. elegans invasive fungal infection in an immunocompromised patien

123 ministered before definitive diagnosis of an invasive fungal infection in critically ill patients wit

124 nd, in some cases, reducing the incidence of invasive fungal infection in critically ill patients.

125 intestinal basidiobolomycosis is an emerging invasive fungal infection in desert regions of the US So

126 Trichosporonosis is an emerging invasive fungal infection in immunosuppressed patients;

127 ective in preventing fungal colonization and invasive fungal infection in infants with birth weights

128 e feasibility of developing vaccines against invasive fungal infection in this fast growing patient p

129 s associated with a significant reduction in invasive fungal infections in high-risk liver transplant

130 pecies, Candida albicans, causes half of all invasive fungal infections in humans.

131 Candida albicans is the most common cause of invasive fungal infections in humans.

132 Candida albicans is the most common cause of invasive fungal infections in humans.

133 a role in influencing the evolving trends in invasive fungal infections in liver transplant recipient

134 on used for prophylaxis and for treatment of invasive fungal infections in OTRs.

135 The incidence of invasive fungal infections in patients receiving aerosol

136 azole is widely used for prophylaxis against invasive fungal infections in patients undergoing myeloa

137 e feasibility of developing vaccines against invasive fungal infections in patients with severe immun

138 lant recipients, accounting for 2% and 8% of invasive fungal infections in recent cohorts of solid-or

139 We assessed the temporal trends in invasive fungal infections in the context of evolution i

140 e saprophytic molds causing life-threatening invasive fungal infections in the immunocompromised host

141 last decade as a common cause of mucosal and invasive fungal infection, in large part due to its intr

142 Seventy-one recipients (21.6%) developed invasive fungal infections, including 29 patients (8.8%)

143 lative incidence rates of proven or probable invasive fungal infections, invasive mold infections, in

144 Invasive fungal infection is associated with substantial

145 The diagnosis of an invasive fungal infection is difficult, and the risk fac

146 endent IL-17A production in the lungs during invasive fungal infection is mediated in part by CD11b(+

147 atment administered prior to diagnosis of an invasive fungal infection is not associated with either

148 The utility of molecular diagnostics in invasive fungal infections is discussed.

149 se within the lung, the primary site of most invasive fungal infections, is unknown.

150 e following: resolution of fever; absence of invasive fungal infection; no discontinuation because of

151 In the ganciclovir group, more invasive fungal infections occurred (P = .03) and more g

152 Invasive fungal infections occurred in 36% (8 of 22) of

153 Proven invasive fungal infections occurred in 6 of 71 itraconaz

154 -6 infection was an independent predictor of invasive fungal infections (odds ratio 8.3, 95% confiden

155 itraconazole was still associated with fewer invasive fungal infections (odds ratio, 0.300 [CI, 0.111

156 Isolated invasive fungal infections of unclear cellular basis are

157 Immunosuppressed patients at high risk for invasive fungal infections often have prolonged or repea

158 1.4; 95% confidence interval [CI], 1.1-1.8), invasive fungal infection (OR, 1.3; 95% CI, 1.1-1.5), an

159 The incidence of invasive fungal infections, particularly invasive candid

160 mmune suppression increases the incidence of invasive fungal infections, particularly those caused by

161 study in 75 marrow transplant patients with invasive fungal infections (primarily Aspergillus or Can

162 rgillus fumigatus, and is a leading cause of invasive fungal infection-related mortality and morbidit

163 Invasive fungal infection remains a serious postoperativ

164 s that describe changes in the likelihood of invasive fungal infections, shifts in types of fungal pa

165 glucocorticoid-induced immunosuppression and invasive fungal infections should assist in earlier reco

166 Mucormycosis is a severe emerging invasive fungal infection that occurs as a consequence o

167 ally review the spectrum and presentation of invasive fungal infections that arise in the setting of

168 anagement of transplant patients at risk for invasive fungal infection warrants a high index of suspi

169 Mortality due to bacteremia or invasive fungal infection was higher among D(+)/R(-) (18

170 has been reported in an Iranian family with invasive fungal infections, we also sequenced CARD9 in t

171 ebo group; P > 0.2), fewer deaths related to invasive fungal infection were seen in the fluconazole g

172 Treatment-related adverse events and invasive fungal infections were quantitated for 2 months

173 associated with lower rates of mortality and invasive fungal infections when administered before defi

174 versy regarding significant risk factors for invasive fungal infection, which has limited the develop

175 Three patients developed invasive fungal infections while on voriconazole prophyl

176 Mucormycosis is a deadly invasive fungal infection whose characteristics are only

177 ole of this new triazole in the treatment of invasive fungal infections will be better defined.

178 Candidemia is a severe invasive fungal infection with high mortality.

179 Invasive fungal infection with positive growth of fungal